(Q59315694)

1

T Tolfvenstam

0 references

Thomas Tolfvenstam

Thomas Tolfvenstam

1

0 references

Kristina Broliden

5

Kristina Broliden

0 references

Britta Wahren

4

Britta Wahren

0 references

Wahren B

4

B Wahren

0 references

author name string

A Lundqvist

2

0 references

M Levi

3

0 references

Anders Lundqvist

2

0 references

Michael Levi

3

0 references

language of work or name

English

0 references

publication date

22 November 2000

0 references

November 2000

0 references

number of pages

6

1 reference

Characterization and Molecular Cloning of a Human Parvovirus Genome

inferred from page(s)

published in

Vaccine

0 references

volume

19

0 references

issue

7-8

0 references

page(s)

758-63

0 references

758-763

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Identification of the region including the epitope for a monoclonal antibody which can neutralize human parvovirus B19.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Two anti-parvovirus B 19 IgM capture assays incorporating a mouse monoclonal antibody specific for B 19 viral capsid proteins VP 1 and VP 2

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Identification and use of a neutralising epitope of parvovirus B19 for the rapid detection of virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Candidate recombinant vaccine for human B19 parvovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

IgG response to the immunoreactive region of parvovirus B19 nonstructural protein by immunoblot assay with a recombinant antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Antibodies to parvovirus B19 NS-1 protein in infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Antibodies to the Nonstructural Protein of Parvovirus B19 in Persistently Infected Patients: Implications for Pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Development of antibodies to the nonstructural protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy: implications for pathogenesis doubtful

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Persistent B19 parvovirus infection in pediatric malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Rapid “tea-bag” peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Immune response to B19 parvovirus and an antibody defect in persistent viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021

Persistent rat parvovirus infection in individually housed rats

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900258-9

7 January 2021